Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Rick Baehner


Joined Exact Sciences: 2019

Rick Baehner has served as our Chief Medical Officer, Precision Oncology since Exact Sciences’ acquisition of Genomic Health in November 2019. Rick joined Genomic Health in 2005 and was named Chief Medical Officer in 2018. Mr. Baehner provides over 15 years of Medical, Pathology, Product Development and management expertise to Exact Sciences Precision Oncology Business. Rick is also an associate professor in the Department of Pathology at the University of California, San Francisco with subspecialty expertise in cytology, breast and molecular pathology. He directed the Hellen Diller Molecular & Immunohistochemistry Core Laboratory for 10 years.

Rick is active in several medical associations including the American Society of Clinical Oncology (ASCO), United States and Canadian Academy of Pathology (USCAP), the College of American Pathologists (CAP), and served on the CAP Immunohistochemistry and Technology Assessment Committees.

Rick holds his Medical Doctorate from the University of Kansas, School of Medicine, and a Bachelors of Arts in Philosophy from the University of Kansas. Rick trained at the University of California, San Francisco and is boarded in Anatomic and Clinical Pathology. He completed Fellowship training programs in Surgical Pathology, Hematopathology and Cytology.